Project: An integrated HTS platform for the discovery of new therapeutics against cardiomyopathies

Acronym	CARDIOMYO (Reference Number: 113937)
Duration	01/06/2020 - 01/12/2023
Project Topic	We will establish an innovative drug discovery platform for the generation of lead compounds against cardiomyopathies. CARDIOMYO combines three complementary approaches: 1) ultraHTS phenotypic in vitro cardiac assays 2) a novel in vivo cardiovascular phenotyping using zebrafish and 3) drug discovery chemistry. The platform will close the current gap between early drug discovery with partially informative cellular tools and preclinical development using costly and complex mammal models.
Network	Eurostars 2
Call	Eurostars Cut–off 12

Project partner

Number	Name	Role	Country
1	Taros Chemicals	Partner	Germany
2	VU University Medical Center	Partner	Netherlands
3	ZeClinics	Coordinator	Spain